UAE-based BioSapien extends pre-Series A round to $7 million

BioSapien, the biotech innovator behind MediChip — a groundbreaking localized cancer treatment platform — has successfully expanded its pre-Series A funding round to $7 million. This achievement includes strategic investment from leading backers, notably Golden Gate Ventures, marking its first investment through its dedicated MENA Fund.

With cancer rates rising and the UAE's progressive healthcare initiatives gaining momentum, now is the perfect time for BioSapien's expansion. Leveraging advanced 3D printing technology, MediChip delivers precise, localized treatment — thus minimizing systemic side effects and enhancing patient outcomes. This innovation aligns with the UAE's commitment to improving quality of life through cutting-edge technology.

The funding underscores BioSapien's dedication to patient-focused oncology solutions while reinforcing the UAE's status as a global health innovation leader. The investment will drive clinical trials in the UAE, set to commence in Q2 2025, for MediChip, BioSapien's patented 3D-printed, slow-release drug delivery platform. Additionally, the capital will support product development and manufacturing scale-up.

The UAE's commitment to advancing medical technology plays a crucial role in BioSapien's mission. The upcoming first-in-region clinical trials mark a key milestone, further positioning Abu Dhabi as a global healthcare innovation hub. This collaboration with local stakeholders highlights the Gulf region's potential in pioneering next-generation treatments to address global healthcare challenges.

This funding extension follows December's $5.5 million pre-Series A round, led by Global Ventures, one of MENA's top VC firms, with additional support from Dara Holdings.

BioSapien's mission is to treat over one million patients by 2035.

Funding 💰

Round $7M
Pre-Series A
Investors Golden Gate Ventures

Quotes 💬

We are delighted to announce our new investment and are grateful for all the support we have received. The expertise and belief in our vision from our investors come at a critical juncture as we initiate clinical trials in Abu Dhabi. Together, we are working towards a future where localised cancer treatment becomes the global standard.
Khatija Ali, CEO and Founder of BioSapien
Having met CEO and Founder Khatija at Hub71 in Abu Dhabi, we were instantly impressed by her passion and vision. Investing in BioSapien aligns with our commitment to supporting transformative technologies that address significant global challenges. This investment not only supports a groundbreaking technology but also reinforces the Gulf region's role as a global leader in healthcare innovation.
Michael Lints, Partner at Golden Gate Ventures MENA

About 🏢

BioSapien is a biotechnology company specializing in innovative cancer treatments. Its flagship product, MediChip, is a 3D-printed, biodegradable implant designed to deliver chemotherapy drugs directly to tumor sites, aiming to minimize systemic side effects commonly associated with traditional chemotherapy. This localized approach targets cancer cells more precisely and enhances patients' quality of life during treatment. The company holds global patents for its platform, with expirations set for 2039. BioSapien's mission is to advance human well-being through innovative solutions, with a goal to treat over one million patients by 2035. In addition to Abu Dhabi, the company has an office in San Diego, California. more
source

💡Did you know?

You can take your DHArab experience to the next level with our Premium Membership.
👉 Click here to learn more